Conantokin-G
Overview
Conantokin-G is a 17-amino acid peptide originally isolated from the venom of the cone snail Conus geographus. It acts as a selective antagonist of N-methyl-D-aspartate (NMDA) receptors containing the NR2B subunit, which are implicated in chronic pain, neuropathic pain, and central sensitization. The peptide contains gamma-carboxyglutamic acid residues that are critical for its activity and metal ion binding. Conantokin-G represents a novel class of non-opioid analgesics targeting glutamatergic neurotransmission.
Key Research Findings
Preclinical studies have demonstrated analgesic and neuroprotective effects of conantokin-G in rodent models of neuropathic pain, epilepsy, and ischemic injury. The peptide showed promise in early safety and pharmacokinetic studies, but clinical development has been limited. Challenges include synthesis complexity, delivery to the central nervous system, and limited clinical trial data in pain populations.
Intrathecal, Intravenous
Investigational
Interested in Conantokin-G?
Find a verified provider experienced with Conantokin-G protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Conantokin-G ProviderRelated Peptides
Ziconotide (Prialt)
FDA ApprovedA synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA, a neurotoxin found in the venom of the marine cone snail Conus magus. Ziconotide selectively and reversibly blocks N-type voltage-gated calcium channels (Cav2.2) in the dorsal horn of the spinal cord, inhibiting neurotransmitter release from primary afferent nociceptive neurons. It provides analgesia without opioid receptor activation, tolerance development, or respiratory depression.
Difelikefalin (Korsuva)
FDA ApprovedA selective kappa-opioid receptor (KOR) agonist peptide that does not cross the blood-brain barrier, providing peripheral analgesia and anti-pruritic effects without central opioid side effects such as euphoria, dysphoria, sedation, or addiction. Difelikefalin activates kappa receptors on peripheral sensory neurons and immune cells to reduce itch signaling and inflammation. Its restricted CNS penetration is a deliberate design feature to avoid abuse potential.
ARA-290
In Clinical TrialsA synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heteromer of the EPO receptor and the beta common receptor (CD131). Unlike EPO, ARA-290 does not stimulate erythropoiesis or promote thrombosis. It produces cytoprotective, anti-inflammatory, and tissue-reparative effects by activating the IRR on neurons, immune cells, and endothelial cells.
Palmitoylethanolamide (PEA)
Research PhaseAn endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to tissue damage and inflammation. PEA acts primarily through peroxisome proliferator-activated receptor alpha (PPAR-alpha), downregulating mast cell activation and pro-inflammatory mediator release. It also modulates the endocannabinoid system via the entourage effect, enhancing anandamide activity at CB1/CB2 receptors and TRPV1 channels without directly binding cannabinoid receptors.